Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET. The event will be webcasted live and accessible through the investor and media section of Esperion's website. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a pharmaceutical company focused on developing innovative medicines for cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next-step solutions in reducing LDL-cholesterol levels. The company emphasizes the importance of lowering cholesterol levels as much as possible, as quickly as possible.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione alla 26ª Conferenza Globale sugli Investimenti Annuale H.C. Wainwright che si terrà lunedì 9 settembre 2024, alle 8:30 a.m. ET. L'evento sarà trasmesso in diretta streaming e sarà accessibile attraverso la sezione dedicata a investitori e media sul sito web di Esperion. Una registrazione sarà disponibile circa due ore dopo la chiamata e archiviata per circa 90 giorni.
Esperion è un'azienda farmaceutica focalizzata sullo sviluppo di medicinali innovativi per le malattie cardiovascolari e cardiometaboliche. La loro missione è aiutare i pazienti con colesterolo alto a raggiungere i loro obiettivi di salute fornendo soluzioni avanzate per ridurre i livelli di colesterolo LDL. L'azienda sottolinea l'importanza di abbassare i livelli di colesterolo il più possibile, il più rapidamente possibile.
Esperion (NASDAQ: ESPR) ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright el lunes 9 de septiembre de 2024, a las 8:30 a.m. ET. El evento se transmitirá en vivo y será accesible a través de la sección de inversores y medios en el sitio web de Esperion. Una repetición estará disponible aproximadamente dos horas después de la llamada y archivada durante unos 90 días.
Esperion es una empresa farmacéutica centrada en desarrollar medicamentos innovadores para enfermedades cardiovasculares y cardiometabólicas. Su misión es ayudar a los pacientes con colesterol alto a alcanzar sus objetivos de salud proporcionando soluciones de siguiente paso para reducir los niveles de colesterol LDL. La empresa enfatiza la importancia de reducir los niveles de colesterol tanto como sea posible, tan rápido como sea posible.
Esperion (NASDAQ: ESPR)는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 2024년 9월 9일 월요일 오전 8:30 (ET)에 참가한다고 발표했습니다. 이 행사는 생중계로 진행되며 Esperion의 웹사이트에 있는 투자자 및 미디어 섹션을 통해 접근할 수 있습니다. 통화 후 약 2시간 후에 다시보기 제공되며 약 90일 동안 아카이브됩니다.
Esperion은 심혈관 및 심혈관 대사 질환을 위한 혁신적인 의약품 개발에 중점을 둔 제약회사입니다. 그들의 사명은 높은 콜레스테롤을 가진 환자들이 LDL 콜레스테롤 수치를 줄이기 위한 다음 단계 솔루션을 제공함으로써 건강 목표를 달성할 수 있도록 돕는 것입니다. 이 회사는 가능한 한 빨리 콜레스테롤 수치를 낮추는 것의 중요성을 강조합니다.
Esperion (NASDAQ: ESPR) a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright qui se tiendra le lundi 9 septembre 2024, à 8h30 ET. L'événement sera diffusé en direct et accessible via la section investisseurs et médias du site web d'Esperion. Une rediffusion sera disponible environ deux heures après l'appel et archivée pendant environ 90 jours.
Esperion est une entreprise pharmaceutique axée sur le développement de médicaments innovants pour les maladies cardiovasculaires et cardiométaboliques. Leur mission est d'aider les patients ayant un taux de cholestérol élevé à atteindre leurs objectifs de santé en fournissant des solutions de prochaine étape pour réduire les niveaux de cholestérol LDL. L'entreprise souligne l'importance de réduire les niveaux de cholestérol autant que possible, le plus rapidement possible.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright am Montag, den 9. September 2024, um 8:30 Uhr ET bekannt gegeben. Die Veranstaltung wird live übertragen und ist über den Investoren- und Medienbereich der Website von Esperion zugänglich. Eine Wiederholung wird etwa zwei Stunden nach dem Anruf verfügbar sein und für etwa 90 Tage archiviert.
Esperion ist ein Pharmakonzern, der sich auf die Entwicklung innovativer Medikamente für Herz-Kreislauf- und kardiometabolische Erkrankungen konzentriert. Ihre Mission ist es, Patienten mit hohem Cholesterinspiegel dabei zu helfen, ihre Gesundheitsziele zu erreichen, indem sie als nächsten Schritt Lösungen zur Senkung der LDL-Cholesterinwerte anbieten. Das Unternehmen betont die Bedeutung, die Cholesterinwerte so weit wie möglich und so schnell wie möglich zu senken.
- None.
- None.
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) participating in the H.C. Wainwright Global Investment Conference?
How can investors access Esperion's (ESPR) presentation at the H.C. Wainwright conference?
How long will the replay of Esperion's (ESPR) conference presentation be available?
What is the main focus of Esperion's (ESPR) pharmaceutical research?
